Entera Bio

3 stories about Entera Bio
נאסד"ק וול סטריט

Fourth Time’s the Charm for Entera Bio IPO

01.07.18|Dror Reich
The Israel-based oral drug developer listed on Nasdaq on Thursday, pricing 1.4 million units of one share and one warrant at $8 each
תרופות  טבע גלולות תרופה

Entera Bio Files for Nasdaq IPO

12.11.17|Lilach Baumer
The clinical stage company develops treatments mostly for osteoporosis and bone disorders
default image

IPO Hopeful Entera Bio Moves to Better Position

13.09.17|Dror Reich
Clinical-stage company Entera Bio develops pioneering technology for orphan disease hypoparathyroidism